These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27753035)

  • 41. High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
    Vasickova P; Machackova E; Lukesova M; Damborsky J; Horky O; Pavlu H; Kuklova J; Kosinova V; Navratilova M; Foretova L
    BMC Med Genet; 2007 Jun; 8():32. PubMed ID: 17561994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.
    Taniguchi K; Uchida J; Nishino K; Kumagai T; Okuyama T; Okami J; Higashiyama M; Kodama K; Imamura F; Kato K
    Clin Cancer Res; 2011 Dec; 17(24):7808-15. PubMed ID: 21976538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer.
    Zhou J; Chang L; Guan Y; Yang L; Xia X; Cui L; Yi X; Lin G
    PLoS One; 2016; 11(7):e0159708. PubMed ID: 27459628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.
    Vendrell JA; Mau-Them FT; Béganton B; Godreuil S; Coopman P; Solassol J
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood.
    Ran R; Li L; Wang M; Wang S; Zheng Z; Lin PP
    Anal Bioanal Chem; 2013 Sep; 405(23):7377-82. PubMed ID: 23828210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal dominant retinitis pigmentosa.
    Sullivan LS; Bowne SJ; Seaman CR; Blanton SH; Lewis RA; Heckenlively JR; Birch DG; Hughbanks-Wheaton D; Daiger SP
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4579-88. PubMed ID: 17003455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements.
    Frederick L; Eley G; Wang XY; James CD
    Neuro Oncol; 2000 Jul; 2(3):159-63. PubMed ID: 11302336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
    Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
    Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.
    Mitiushkina NV; Iyevleva AG; Poltoratskiy AN; Ivantsov AO; Togo AV; Polyakov IS; Orlov SV; Matsko DE; Novik VI; Imyanitov EN
    Cancer Cytopathol; 2013 Jul; 121(7):370-6. PubMed ID: 23408463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
    Kimura H; Nishikawa S; Koba H; Yoneda T; Sone T; Kasahara K
    Adv Exp Med Biol; 2016; 924():171-174. PubMed ID: 27753039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.
    Parisi C; Mastoraki S; Markou A; Strati A; Chimonidou M; Georgoulias V; Lianidou ES
    Clin Chim Acta; 2016 Oct; 461():156-64. PubMed ID: 27510924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
    Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
    Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.
    Campbell PJ; Stephens PJ; Pleasance ED; O'Meara S; Li H; Santarius T; Stebbings LA; Leroy C; Edkins S; Hardy C; Teague JW; Menzies A; Goodhead I; Turner DJ; Clee CM; Quail MA; Cox A; Brown C; Durbin R; Hurles ME; Edwards PA; Bignell GR; Stratton MR; Futreal PA
    Nat Genet; 2008 Jun; 40(6):722-9. PubMed ID: 18438408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CUT-PCR: CRISPR-mediated, ultrasensitive detection of target DNA using PCR.
    Lee SH; Yu J; Hwang GH; Kim S; Kim HS; Ye S; Kim K; Park J; Park DY; Cho YK; Kim JS; Bae S
    Oncogene; 2017 Dec; 36(49):6823-6829. PubMed ID: 28846115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of personalized tumor biomarkers using massively parallel sequencing.
    Leary RJ; Kinde I; Diehl F; Schmidt K; Clouser C; Duncan C; Antipova A; Lee C; McKernan K; De La Vega FM; Kinzler KW; Vogelstein B; Diaz LA; Velculescu VE
    Sci Transl Med; 2010 Feb; 2(20):20ra14. PubMed ID: 20371490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
    Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Patel SP; Harismendy O; Ikeda M; Parker BA; Kurzrock R
    Clin Cancer Res; 2016 Nov; 22(22):5497-5505. PubMed ID: 27185373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of Circulating Tumor DNA.
    Mithraprabhu S; Spencer A
    Methods Mol Biol; 2018; 1792():129-145. PubMed ID: 29797256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas.
    Tsoi KM; Gokgoz N; Darville-O'Quinn P; Prochazka P; Malekoltojari A; Griffin AM; Ferguson PC; Wunder JS; Andrulis IL
    Bone Joint Res; 2021 Sep; 10(9):602-610. PubMed ID: 34558310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.
    Olsson E; Winter C; George A; Chen Y; Howlin J; Tang MH; Dahlgren M; Schulz R; Grabau D; van Westen D; Fernö M; Ingvar C; Rose C; Bendahl PO; Rydén L; Borg Å; Gruvberger-Saal SK; Jernström H; Saal LH
    EMBO Mol Med; 2015 Aug; 7(8):1034-47. PubMed ID: 25987569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.